Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_assertion type Assertion NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_head.
- NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_assertion description "[Furthermore, COX-2 may be a therapeutic target for CIS because of the high expression rate of COX-2 in CIS lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_provenance.
- NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_assertion evidence source_evidence_curated NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_provenance.
- NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_assertion SIO_000772 10873095 NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_provenance.
- NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_assertion wasDerivedFrom ctd_human-20130708 NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_provenance.
- NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_assertion wasGeneratedBy ECO_0000218 NP27821.RA5PSIgmmk-rUwJdhOTMR4fiNRPaJVR2wc5sqfGxtmj_s130_provenance.